Search results
Results from the WOW.Com Content Network
Axicabtagene ciloleucel. Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. [ 8] T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor.
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
Brexucabtagene autoleucel is a chimeric antigen receptor T cell therapy and is the first cell-based gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma. [ 10] Brexucabtagene autoleucel was approved for medical use in the United States in July 2020, [ 10][ 7][ 13] and in the European ...
Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Moffitt Cancer Center & Research Institute is a nonprofit cancer treatment and research center located in Tampa, Florida. Established in 1981 by the Florida Legislature, the hospital opened in October 1986 on the University of South Florida's campus. [ 2] Moffitt is one of two National Cancer Institute-designated Comprehensive Cancer Centers ...
August 16, 2024 at 9:57 AM. Haywood Park Community Hospital was the closest hospital for many in Brownsville, Tennessee, a rural city in the eastern part of the state. Some residents believe it ...
Veterans who support the treatment say it would jeopardize patients suffering from PTSD who haven’t been helped by antidepressants and other existing therapies. The suicide rate among veterans ...
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer ( adoptive cell transfer ). [ 10][ 7] Serious side effects occur in most patients. [ 9] The most common serious side effects are cytokine release ...